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Abstract
Chronic pain is a distressing condition, which is experienced
even when the painful stimulus, whether surgery or disease
related, has subsided. Current treatments for chronic pain
show limited efﬁcacy and come with a host of undesirable
side-effects, and thus there is a need for new, more effective
therapies to be developed. The mechanisms underlying
chronic pain are not fully understood at present, although
pre-clinical models have facilitated the progress of this
understanding considerably in the last decade. The mecha-
nisms underlying chronic pain were initially thought to be
neurocentric. However, we now appreciate that non-neuronal
cells play a signiﬁcant role in nociceptive signalling through
their communication with neurons. One of the major signalling
pathways, which mediates neuron/non-neuronal communica-
tion, is chemokine signalling. In this review, we discuss
selected chemokines that have been reported to play a pivotal
role in the mechanisms underlying chronic pain in a variety of
pre-clinical models. Approaches that target each of the
chemokines discussed in this review come with their advan-
tages and disadvantages; however, the inhibition of chemo-
kine actions is emerging as an innovative therapeutic strategy,
which is now reaching the clinic, with the chemokine
Fractalkine and its CX3CR1 receptor leading the way.
Keywords: chemokines, chronic pain, proteases, therapy.
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This article is part of the special article series “Pain”.
Chronic pain is a distressing, debilitating condition, which is
poorly managed by clinically available drugs at present. It
manifests in a variety of ways, with patients experiencing
spontaneous pain, pain in response to innocuous stimuli
(allodynia), heightened sensitivity to noxious stimuli (hyper-
algesia) or irregular, unpleasant sensations (dysesthesia).
Chronic pain can accompany a variety of injuries and
conditions that result in lesions or dysfunction of the
somatosensory nervous system and can continue for months
or years after the initial tissue damage has healed. Such
injuries include peripheral nerve injury (post-surgical);
damage to the central nervous system as a result of
conditions such as multiple sclerosis (Watson and Sandroni
2016); injury resulting from viral infections (Uebelacker
et al. 2015); metabolic disorders, such as diabetes (Davies
et al. 2006); autoimmune disorders, such as rheumatoid
arthritis (Wolfe et al. 2011) and injury as a result of drug
treatment, such as chemotherapy (Dougherty et al. 2007).
Current treatments for chronic pain come with a host of
undesirable side-effects and provide only limited relief to
patients. Because of the fact that the underlying mechanisms
are not fully understood, effective therapies have yet to be
developed. Substantial advances in our understanding of the
mechanisms underlying chronic pain have been facilitated by
murine pre-clinical studies, which model chronic pain through
surgical, pharmacological and immunization methods.
Chronic pain was historically attributed to a purely
neuronal response to injury, which resulted in the develop-
ment of ‘neurocentric’ strategies, in other words, therapies
that focused on targeting neurons. However, extensive pre-
clinical evidence has now implicated signiﬁcant contribu-
tions of non-neuronal cells in the regulation of chronic pain
and, in particular, has identiﬁed a pivotal role of neuron/non-
neuronal cell cross-talk in the modulation of nociceptive
signalling. The development of alternative therapeutic
strategies has therefore now shifted focus towards targeting
the activation of non-neuronal cells, as well as the multitude
of factors released by them, in response to nerve and tissue
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injury. Although the ultimate aim of developing new
therapies is to dampen the neuronal signalling associated
with pain, the novelty now comes with the target, which is no
longer neurocentric.
One of the major ligand/receptor partnerships that facilitate
communication between neurons and neighbouring non-
neuronal cells in the nervous system is chemokine signalling
(Ramesh et al. 2013). Chemokines, or ‘chemotactic cytoki-
nes’, which were ﬁrst identiﬁed over two decades ago as
mediators of leucocyte migration (Oppenheim et al. 1991),
are a family of small proteins, typically ranging from 8 to 17
kDa in size. Chemokines are classiﬁed according to the
organization of cysteine residues on their N-terminal region
and are thus divided into four subfamilies: C, CC, CXC and
CX3C (Luster 1998; Bajetto et al. 2002; Laing and
Secombes 2004). Chemokines can be released by a variety
of cell types in the central nervous system such as microglia,
astrocytes and neurons (Bajetto et al. 2002). Various cell
types in the peripheral nervous system also have the capacity
to express chemokines, for instance, nociceptive sensory
neurons in the dorsal root ganglia (Miller et al. 2008) as well
as inﬁltrating monocytes/macrophages and Schwann cells,
which constitute the myelin sheath surrounding axons
(Kopydlowski et al. 1999; Saika et al. 2012).
While expressed in multiple cell types, in some cases the
expression of a speciﬁc chemokine is restricted to a particular
cell type, for instance, CX3CL1 is principally expressed by
neurons (Clark et al. 2009). In most cases, signalling
between chemokines and their receptors is promiscuous with
one chemokine having the capacity to activate multiple
chemokine receptors. For example, chemokine (C–C motif)
ligand (CCL)3 is able to activate chemokine receptor (CCR)
1, 5 and 9 (Kunkel 1999). In addition, one chemokine
receptor can be activated by multiple chemokines. For
instance, the CCR5, is activated by multiple chemokines
(Combadiere et al. 1996; Raport et al. 1996; Samson et al.
1996; Nibbs et al. 1999).
Themajority of chemokines are not constitutively expressed
in the nervous system but are instead induced during adverse
conditions (Bajetto et al. 2002). The latter feature makes
chemokines particularly useful as therapeutic targets, because
of the fact that their inhibition would be less likely to interfere
with homeostatic processes, thus reducing adverse side-
effects. In addition, chemokine receptors are G protein-
coupled receptors, which are the most commonly targeted
receptor class in modern medicine (Wells et al. 2006).
Chemokines have recently been associated with a variety
chronic pain conditions clinically. For instance, the homeo-
static chemokine CX3CL1, has been reported to be elevated
in the bone marrow of rheumatoid arthritis patients (Kuca-
Warnawin et al. 2016). In addition, chemokines such as
CCL2 and CCL17 have been observed in blood samples taken
from temporomandibular disorder and ﬁbromyalgia patients
respectively (Slade et al. 2011; Garcıa et al. 2013). This
highlights the importance and validity of investigating the
role in chemokines in chronic pain disorders. Here, we
discuss pre-clinical evidence for the role of a selected number
of chemokines in neuron-non-neuronal cell communication
in the context of chronic pain and consider the therapeutic
potential of disrupting their signalling.
CX3CL1/fractalkine
Expression and distribution
CX3CL1, otherwise known as fractalkine (FKN), is the only
member of the CX3C subfamily of chemokines. In the CNS,
FKN is expressed predominantly by neurons and unlike the
majority of chemokines, is expressed constitutively. Indeed,
in the spinal cord, expression of FKN is restricted only to
neurons under basal conditions (Lindia et al. 2005; Clark
et al. 2009; Yang et al. 2012). In the peripheral nervous
system, FKN expression has been observed in the cell bodies
of sensory neurons in the dorsal root ganglia (Verge et al.
2004). The expression of FKN at the central terminals of
these neurons in the spinal cord, however, is debated with
studies reporting both a presence (Verge et al. 2004) and
absence (Clark et al. 2009) of FKN at this location. When
the FKN expression proﬁle was examined in a FKN reporter
mouse (Kim et al. 2011), however, it was conﬁrmed that
neurons in the CNS did indeed express FKN, but sensory
neurons in the dorsal root ganglion (DRG) as well as their
terminals in the spinal cord, did not (Fig. 1). In the periphery,
FKN is constitutively expressed in endothelial cells in the
skin and intestine (Papadopoulos et al. 1999; Muehlhoefer
et al. 2000) as well as in the heart (Harrison et al. 1999) and
lungs (Foussat et al. 2000).
FKN exists as both a full length, membrane-bound form of
approximately 100 kDa in size, and a cleaved, soluble form
(sFKN) of 80 kDa in size, making this chemokine an
anomaly compared to other chemokines in terms of size, with
other chemokines typically not exceeding 17 kDa. The
cleavage of FKN is both constitutive and inducible.
The membrane-bound form serves an adhesion function in
the context of the vascular immune system, and regulates the
ﬁrm adhesion of leucocytes without the activation of
integrins (Fong et al. 1998). sFKN, however, functions as
a chemoattractant for T cells, B cells, Natural Killer (NK)
cells and monocytes (Imai et al. 1997; Corcione et al. 2009)
and is essential for the trans-endothelial migration of
monocytes that express the FKN receptor (Auffray et al.
2007). The cleavage of FKN and thus its shedding from the
cell membrane is dependent on two classes of proteases,
namely, metalloproteases (ADAM 10 and ADAM 17), which
are expressed by endothelial cells (Hundhausen et al. 2007;
Hurst et al. 2009) and the cysteine protease cathepsin S
(CatS), which is released by microglia in the spinal cord
(Clark et al. 2009). While ADAM 10 regulates the consti-
tutive cleavage of FKN (Hundhausen et al. 2003), cleavage
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Fig. 1 Schematic representation of chemokine/chemokine receptor
expression in the dorsal horn of the spinal cord and the peripheral
nervous system. Chemokines shown in purple have been less
extensively studied. (a) The ﬁrst pain synapse in the dorsal horn. A
major signalling partnership that regulates neuron-microglia commu-
nication in nociception is fractalkine (FKN)/CX3CR1 signalling. FKN
is expressed exclusively on neurons in the dorsal horn and is
cleaved by Cathepsin S (CatS), which is released by neighbouring
microglia, to produce soluble FKN (sFKN). sFKN activates CX3CR1
receptors expressed by microglia. Dorsal horn neurons have also
been shown to express chemokine (C–C motif) ligand 2 (CCL2),
however, the expression of the chemokine receptor (CCR)2 recep-
tor, is unclear. Dorsal horn neurons also express CXCL13, which
activates CCR5 receptors expressed by astrocytes. CCR5 receptors
are also activated by CCL3, which is expressed by microglia.
Afferent nerve terminals in the dorsal horn also express chemokines
associated with chronic pain, speciﬁcally CCL21, which has the
capacity to activate both CXCR3 and CCR7 receptors expressed by
microglia, the latter of which is induced in chronic pain. (b) In the
dorsal root ganglion, FKN has been reported to be expressed by
sensory neurons (however, this is controversial, see Kim et al.
2011). sFKN activates CX3CR1 receptors, which are expressed by
macrophages. Macrophages in the dorsal root ganglion (DRG) also
express the CCR2 receptor, which is activated by CCL2 released
from both CGRP and TRPV1-positive sensory neurons. CGRP-
positive sensory neurons also express CCL21, although CCL21
actions in the DRG are not established. (c) In the periphery, FKN is
expressed by endothelial cells, and is cleaved by CatS, which is
found in monocytes/macrophages. sFKN activates CX3CR1 recep-
tors, also expressed by monocytes/macrophages. Both macro-
phages and Schwann cells also express CCL4, which can activate
CCR5 receptors expressed by macrophages. Endothelial cells also
express CCL2, which activates CCR2 receptors in monocytes/
macrophages.
© 2016 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
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by ADAM 17 and CatS are induced in adverse conditions
(Clark et al. 2009; Hurst et al. 2009). The ADAMs and CatS
target membrane-bound FKN at different cleavage sites and
therefore give rise to different forms of sFKN, which could
serve subtly different functions.
Unlike other, typically promiscuous, chemokines, FKN
exclusively activates the CX3CR1 receptor. CX3CR1 was
initially identiﬁed in humans and rats around 20 years ago
(Harrison et al. 1994; Imai et al. 1997) and is a seven
transmembrane domain G protein-coupled receptor, specif-
ically of the Gi and Gz subtypes (Al-Aoukaty et al. 1998).
The expression proﬁle of CX3CR1 has been most extensively
characterized using the CX3CR1-GFP reporter mouse line,
with the receptor present in murine monocytes
(CD11b+Gr1low), NK cells, myeloid and lymphoid dendritic
cells and in a subset of cutaneous Langerhans cells (Jung
et al. 2000). In the nervous system speciﬁcally, CX3CR1
appears to be exclusively expressed in microglia in the spinal
cord and brain (Lindia et al. 2005; Yang et al. 2012; Clark
et al. 2013).
One caveat to our current understanding of FKN/CX3CR1
expression is that initial studies in which expression has been
characterized have relied entirely on antibodies. In some
cases, such antibodies have since been shown to be
unreliable in the light of the development of transgenic
mice, often giving false-positives. It is therefore prudent to
assume that expression patterns revealed by antibodies are
only bona ﬁde expression if conﬁrmed in transgenic mice.
Inconsistent ﬁndings regarding expression must be inter-
preted with caution and cannot form the basis of therapy
development. Here, we will consider selected, critical studies
that have used both antibodies and transgenic lines, in which
both approaches have been in agreement with each other.
The distribution of FKN and CX3CR1 in the spinal cord,
which has indeed been conﬁrmed by both antibodies and the
use of transgenic mice, is predominantly neuronal and
microglial respectively. This strongly indicates that this
signalling pair has the potential to mediate neuron-microglial
communication, both homeostatic and pathological.
CX3CL1/R1 signalling in pre-clinical models of
chronic pain
Central mechanisms
The ﬁrst synapse in the nociceptive pathway – between the
terminals of the primary afferents and dorsal horn neurons in
the spinal cord – is a key site at which the modulation of
nociceptive signalling occurs. It is well established that
damage to peripheral nerves, such as the sciatic nerve,
disrupts homoeostasis and consequentially results in height-
ened response states of microglia and astrocytes in the spinal
cord (McMahon and Malcangio 2009). This heightened
microglial activity results in an increase in neuron-microglial
communication, which has the capacity to amplify
nociceptive transmission, resulting in a chronic pain state.
In the dorsal horn of the spinal cord, the distribution of FKN
and CX3CR1, neuronal and microglial, respectively, makes
this signalling pair an ideal candidate for the mediation of
this increase in communication. Indeed, in the last decade,
pre-clinical studies have advanced our understanding of, and
established the role of FKN/CX3CR1 signalling in chronic
pain; thus, bringing the therapeutic potential of targeting this
signalling pathway into prominence.
FKN, sFKN in particular, has been shown to be prono-
ciceptive, with intrathecal administration of the FKN domain,
but not the full length FKN, resulting in both thermal and
mechanical hypersensitivity (Clark and Malcangio 2012;
Clark et al. 2007; Zhuang et al. 2007). This effect is
mediated by CX3CR1 activation (Clark et al. 2007; Staniland
et al. 2010), which in turn induces intracellular phosphory-
lation of microglial p38 MAPK (Clark et al. 2007; Zhuang
et al. 2007) resulting in the release of proinﬂammatory
mediators such as Interleukin 1b (IL-1b), Interleukin 6 (IL-6)
and nitric oxide (Milligan et al. 2005).
Because of the pronociceptive nature of sFKN/CX3CR1
signalling, the inhibition of this pathway is intuitively a
potential therapeutic strategy for the treatment of chronic
pain. Indeed, changes in FKN/CX3CR1 signalling in pre-
clinical models of chronic pain as well as the therapeutic
potential of disrupting such signalling, has been extensively
investigated. Following injury to peripheral nerves, the
expression of CX3CR1 in spinal microglia increases signif-
icantly (Zhuang et al. 2007; Staniland et al. 2010). It is
important to keep in mind, however, that the elevated levels
reported could be because of proliferation of CX3CR1-
expressing microglia and therefore increased expression of
CX3CR1-expressing cells as opposed to elevated CX3CR1
expression per se. Although the general consensus is that the
expression of total (membrane-bound and cleaved) FKN
remains unchanged following peripheral nerve injury (Clark
et al. 2009; Old et al. 2014), levels of sFKN speciﬁcally in
CSF do appear to increase (Clark et al. 2009; Nieto et al.
2016). Chronic pain models are therefore accompanied by an
increase in both sFKN speciﬁcally and CX3CR1.
In various pre-clinical models of peripheral nerve injury,
the intrathecal administration of neutralizing antibodies
against either FKN or CX3CR1 have been found to delay
or attenuate chronic pain-associated behaviours (Milligan
et al. 2004; Clark et al. 2007; Zhuang et al. 2007) through a
reduction in p38 MAPK phosphorylation in microglia and, in
turn, a reduction in the release of proinﬂammatory cytokines
and dampening of neuron–glia communication (Zhuang
et al. 2007). The therapeutic beneﬁts of CX3CR1 inhibition
and thus reduced phosphorylation of microglial p38 MAPK,
also extend to other models of chronic pain, such as bone
cancer, which is also accompanied by microgliosis and
elevation of microglial CX3CR1 and p38 MAPK (Yin et al.
2010; Hu et al. 2012). Indeed, intrathecal delivery of a
© 2016 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
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CX3CR1 neutralizing antibody delayed chronic pain-asso-
ciated behaviour in this model as well as reduced microglio-
sis and the associated increases in CX3CR1 and p38
phosphorylation.
The role of FKN/CX3CR1 modulation of neuron-micro-
glial signalling in chronic pain has also been investigated
using CX3CR1 knock-out mice, which consistently display
deﬁcits in chronic pain in various pre-clinical models,
whether they are traumatic or non-traumatic. For example,
CX3CR1 knock-out mice that are subjected to partial sciatic
nerve ligation (PSNL) display reduced mechanical and
thermal hypersensitivity compared to wild-type mice that
undergo the same procedure (Staniland et al. 2010). This
deﬁcit in chronic pain-associated behaviour observed in
CX3CR1 knock-out mice is correlated with a reduction in
microglial activity. In the case of PSNL, the inﬁltration of
macrophages in the sciatic nerve, the site of injury, was not
altered in CX3CR1 knock-out mice (Staniland et al. 2010),
and so it appears that the reduction in pain behaviour
observed in these animals is mediated speciﬁcally by
CX3CR1-dependent microglial activity in the spinal cord.
The role of CX3CL1/FKN cleavage by CatS in chronic pain
Because of the fact that sFKN speciﬁcally has been found to
increase following peripheral nerve injury and is pronoci-
ceptive, changes in CatS, which regulates cleavage and hence
shedding of FKN to form sFKN, has also received attention
in recent years in the context of chronic pain pre-clinical
models. Following injury to peripheral nerves, CatS expres-
sion increases in microglia that are located in areas of the
spinal cord that are innervated by the injured peripheral
afferents (Clark et al. 2007) and it is subsequently released
from microglia downstream of P2X7 receptor signalling
(Clark et al. 2010). This P2X7-dependent release of CatS
results in the shedding of sFKN from neurons in the dorsal
horn, which in turn, signals to CX3CR1-expressing microglia
(Clark et al. 2007).
The pronociceptive effects of CatS have also been
established ex vivo. For example, in spinal cord slices,
which have been prepared from neuropathic animals and still
have the damaged dorsal root attached, electrical stimulation
of the injured dorsal roots results in the liberation of FKN,
indicative of activated or elevated CatS (Clark et al. 2009).
This liberation of sFKN appears to only be apparent under
conditions in which the microglia are reactive, for example,
injury or lipopolysaccharide (a macrophage activator) expo-
sure (Clark et al. 2009). In addition, the pronociceptive
effects of intrathecal delivery of CatS in vivo are prevented
by neutralization of spinal FKN and in CX3CR1 knock-out
mice (Clark et al. 2007).
The therapeutic potential of inhibiting CatS appears to be
most promising for the maintenance phase of chronic pain as
opposed to the initial induction. Both systemic (Irie et al.
2008; Zhang et al. 2014) and intrathecal (Clark et al. 2007)
delivery of a CatS inhibitor reversed established injury-
induced neuropathic pain, but was not effective if adminis-
tered during the initial phase of pain (e.g. day 3 post-
surgery), at which time, CatS expression was relatively low
in the spinal cord (Clark et al. 2007; Zhang et al. 2014) and
peripherally (Barclay et al. 2007). Furthermore, CatS knock-
out mice demonstrate similar levels of chronic pain to wild-
type controls during initial phases of peripheral injury
models but display lower levels of pain relative to wild-
type controls from day 3, at which point, pain is considered
to have entered the maintenance phase (Zhang et al. 2014).
The inhibition of CatS has also been shown to have
therapeutic potential in non-surgical pre-clinical models of
chronic pain, for example, murine Rheumatoid Arthritis
(RA). Rats with collagen-induced arthritis displayed mechan-
ical hypersensitivity as well as microglial activation and an
elevation of IL-1b in the CSF, all of which was prevented by
intrathecal administration of N-morpholinurea-homopheny-
lalanyl-leucyl-vinylsulfonemethyl (LHVS), a selective CatS
inhibitor (Nieto et al. 2016). CatS-mediated release of sFKN
therefore appears to mediate chronic pain maintenance and
could provide a therapeutic target that has potential where
other current therapies have shown limited efﬁcacy, acting as
an alternative or complementary addition to currently
available drugs. Indeed, in a recent study, the use of a CatS
inhibitor has been shown to enhance the effects of gabapentin
and pregabalin in a PSNL model in rats, as well as resulting
in a dose-dependent attenuation of injury-induced allodynia
when used alone (Hewitt et al. 2016).
Peripheral mechanisms
FKN/CX3CR1 signalling in the spinal cord is a promising
therapeutic target; however, it is now thought to not be the
only location at which this signalling partnership can mediate
chronic pain, with FKN/CX3CR1 signalling in the periphery
also being implicated in models of chemotherapy-induced
painful neuropathy (CIPN). In paclitaxel-treated rats for
instance, the expression of FKN has been reported to
increase in primary sensory neurons in the DRG in vivo and
in vitro and macrophage inﬁltration into the DRG is reported
to increase alongside the development of allodynia (Huang
et al. 2014). Intrathecal administration of a FKN-neutralizing
antibody was shown to prevent macrophage recruitment to
the DRG and reduced activation of p38 MAPK in
macrophages in addition to attenuating paclitaxel-induced
allodynia (Huang et al. 2014). The role of FKN/CX3CR1
signalling in sensory neurons in the DRG, however, should
be interpreted with caution because of the fact that FKN
expression in the DRG is controversial, with contradictory
expression patterns being reported, as discussed above.
Indeed, the lack of evidence for sensory neuron expression in
the FKN reporter transgenic line (Kim et al. 2011) suggests
that FKN is unlikely to be expressed in neurons in the DRG
and any analgesics effects of its inhibition could be because
© 2016 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
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of CX3CR1 inhibition in macrophages in the DRG, (Old
et al. 2014).
In an alternative model of CIPN, Vincristine-induced
neuropathic pain, FKN/CX3CR1 signalling in macrophages
that have been recruited to the sciatic nerve following
vincristine treatment has provided an additional therapeutic
target (Old et al. 2014). Vincristine treatment triggers the
recruitment of CX3CR1-expressing monocytes/macrophages
to the sciatic nerve, with CX3CR1 in this location being
activated by endothelial FKN (Fig. 1). This results in the
downstream activation of Transient receptor potential cation
channel, subfamily A, member 1 (TRPA1) receptors in
sensory neurons as well as the generation of reactive
oxygen species (Old et al. 2014). In this model of CIPN,
CX3CR1 knock-out mice display a delayed onset in
mechanical allodynia, which resembles the delay accompa-
nying depletion of macrophages using low-dose clodronate
liposomes, and a decrease in inﬁltrating macrophages.
Critically, no neuronal damage is observed in this model
and there are no changes to microglial activity in the dorsal
horn of the spinal cord, indicating that in this particular
model, FKN/CX3CR1 signalling in the periphery as
opposed to the spinal cord, plays a role in chronic pain
(Old et al. 2014).
FKN/CX3CR1 signalling therefore provides a promising
prophylactic target for the development of pain. Indeed the
high ﬁdelity of the partnership ensures that therapies targeted
towards this signalling pair are highly speciﬁc relative to
other therapeutic approaches. One caveat, however, is that
unlike the majority of chemokines, FKN is constitutively
expressed in neurons as well as a multitude of cells of the
immune system suggesting that it also plays an essential role
in homeostatic processes, which could be disrupted if
signalling is inhibited and could therefore lead to side-
effects. This highlights the importance of targeting sFKN
speciﬁcally, which could be achieved by targeting CatS, as
opposed to full length FKN or CX3CR1. Nonetheless, the
FKN/CX3CR1 signalling partnership provides unique thera-
peutic potential, which is already being appreciated in
chronic pain conditions and indeed in other pathological
conditions beyond pain, such as pancreatic disease (D’Haese
et al. 2010).
CCL2/MCP-1
Expression and distribution
Another chemokine, which has received much attention in
the context of chronic pain is CCL2. CCL2 or monocyte
chemoattractant protein 1 (MCP-1) recruits monocytes to the
site of infection, ischaemia or inﬂammation. While CCL2 is
able to recognize the receptors CCR1, 2 and 4, it shows
preference for CCR2 (Jung et al. 2009). The expression of
CCL2 in primary sensory neurons has been well studied.
Under basal conditions, low levels of CCL2 are constitutively
expressed in more than 40% of small and medium DRG
neurons, with co-expression being observed with substance
P, Calcitonin gene-related peptide (CGRP) and the Transient
receptor potential cation channel, subfamily V, member 1
(TRPV1) (Tanaka et al. 2004; Dansereau et al. 2008). The
expression of CCL2 has been found to increase in several
pathological conditions. For instance, following PSNL, the
expression of CCL2 increased rapidly in DRG neurons,
within 4 h of the injury occurring (Tanaka et al. 2004).
Likewise, following nerve constriction, CCL2 expression
was found to be induced in both small and large diameter
neurons in the DRG that also expressed ATF3, an indicator
of neuronal injury (Zhang and De Koninck 2006). The
expression of the CCR2 receptor, for which CCL2 has the
highest afﬁnity, has also been well documented in several
models of chronic pain. For example, in situ hybridization
shows that chronic constriction of the DRG results in an
increase in the expression of CCR2 mRNA in both neuronal
and satellite cells in the compressed DRG as well as the
adjacent, non-compressed DRG (White et al. 2005). An
increase in CCR2 expression has also been observed in the
DRG following sciatic nerve demyelination (Jung et al.
2009).
Expression of CCL2/R2 in the spinal cord, however, is
controversial (Fig. 1). CCL2 has been reported to be
constitutively expressed in a variety of cell types, having
been observed in primary afferent neurons (Zhang and De
Koninck 2006) as well as co-localizing with the astrocytic
marker, Glial ﬁbrillary acidic protein (GFAP) (Gao et al.
2009). Expression in astrocytes appears to increase following
the induction of different injury models, for example, spinal
nerve ligation (Gao et al. 2009), spinal cord contusion injury
(Knerlich-Lukoschus et al. 2008) and demyelinating lesions
(Van Der Voorn et al. 1999). Thus, CCL2 expression in
astrocytes appears to be elevated in the spinal cord following
neuronal injury, regardless of the nature. The expression
proﬁle of CCR2 remains debated, with different detection
methods producing conﬂicting results. In CCR2-GFP reporter
mice, for example, a weak but positive GFP signal is
apparent in dorsal horn neurons. In situ hybridization,
however, suggests an absence of CCR2 mRNA in the spinal
cord under basal conditions (Jung and Miller 2008). What
has been more consistently reported, however, is the
elevation of CCR2 in the spinal cord following nerve injury.
For instance, an increase in CCR2 mRNA in the deep dorsal
horn and motor neurons has been reported 3 days after spinal
nerve injury (Gao et al. 2009). Furthermore, an elevation in
CCR2 has been reported in spinal microglia following sciatic
nerve injury (Abbadie et al. 2003; Thacker et al. 2009) as
well as in astrocytes following spinal cord contusion
(Knerlich-Lukoschus et al. 2008). However, the reliability
of antibodies used to detect the presence of CCR2 has been
recently doubted and the precise expression proﬁle of CCR2
in the spinal cord has yet to be ﬁrmly established.
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The fact that both CCL2 and CCR2 have previously been
suggested to increase in pre-clinical models of pain and were
initially thought to be located in neurons and microglia,
respectively (although expression is debatable and not
exclusive to one cell type), makes this signalling pair another
potential player in the mechanisms underlying chronic pain,
which has received considerable attention over the last
decade.
CCL2/R2 signalling in pre-clinical models of chronic pain
Initial studies investigating CCL2/CCR2 signalling in the
spinal cord suggested that this signalling pair played a
considerable role in neuron-microglial communication in
chronic pain animal models. For instance, in ex vivo
preparations of the dorsal horn of the spinal cord, CCL2
levels obtained from spinal cord superfusates, while similar
in unstimulated naive and neuropathic animals, were only
elevated as a result of supramaximal electrical stimulation of
the dorsal root in neuropathic animals, which also displayed
heightened mechanical hypersensitivity (Thacker et al.
2009). In addition, application of intraspinal CCL2 in na€ıve
rats resulted in chronic pain-like behaviour, while intrathecal
delivery of a CCL2-neutralizing antibody inhibited injury-
associated pain behaviour (Thacker et al. 2009). This
suggests that CCL2 is released in an activity-dependent
manner and in turn is able to regulate nociceptive signalling.
CCL2 has also been suggested to play a role in non-
traumatic pre-clinical models of chronic pain, such as CIPN.
In the paclitaxel model of CIPN, for instance, CCL2 is
reported to be elevated in the spinal cord of paclitaxel-treated
mice, which display paclitaxel-induced cold hyperalgesia.
Intrathecal administration of an antibody against CCL2 not
only completely suppressed the hyperalgesia, but also
inhibited paclitaxel-induced microglial activation (Pevida
et al. 2013). This suggests that cold hyperalgesia associated
with paclitaxel therapy could be treated by targeting CCL2-
mediated activation of microglia (either directly or indir-
ectly). CCL2 signals through both CCR2 and CCR1 and
while CCR2 inhibition appears to alleviate paclitaxel-induced
allodynia, CCR1 inhibition does not (Pevida et al. 2013).
This suggests that the pronociceptive effects of CCL2 are
mediated via the CCR2 receptor. A caveat to this ﬁnding,
however, is that the CCR2 inhibitor in the paclitaxel mouse
model has been shown to have additional effects on NMDA
receptor subunit expression and neuronal nitric oxide
synthase (Ren et al. 2015). Both neuronal nitric oxide
synthase and the NMDA receptor subunit; NR2B have been
found to increase and be associated with pain-like behaviour
in a model of bone cancer chronic pain and they are down-
regulated in parallel to the alleviation of allodynia when the
CCR2 inhibitor is administered (Ren et al. 2015). It is
therefore possible that the analgesic effects of CCR2
inhibitors in some pre-clinical models are not because of
the inhibition of CCL2/R2 signalling, but additional, non-
speciﬁc effects, which could weaken the prominence of
CCL2 signalling in the spinal cord in the underlying
mechanisms of pain.
CCL2 expressed elsewhere, however, for example, the
DRG, could still be involved in mechanisms underlying other
forms of pain that are induced by paclitaxel. Paclitaxel has
been shown to induce the expression of CCL2 and CCR2 in
the primary sensory neurons of the DRG, speciﬁcally small,
nociceptive neurons and medium-sized neurons respectively
(Zhang et al. 2013). Local blockade of CCL2/R2 signalling
using either a neutralizing antibody against CCL2 or a CCR2
antisense oligodeoxynucleotide signiﬁcantly reduced pacli-
taxel- target for CIPN.
While there is strong associated allodynia (Zhang et al.
2013), suggesting that neuronal CCL2/R2 signalling in the
DRG could provide a therapeutic evidence to suggest that
CCL2/R2 signalling in the DRG, and potentially the spinal
cord, could play a role in chronic pain, the debatable
and non-exclusive expression proﬁles of both CCL2 and
CCR2 currently limits their potential as therapeutic targets
and this signalling partnership is in need of further
investigation and clariﬁcation in order to be translated to
the clinic.
Other chemokines in neuropathic pain
Although CX3CL1/FKN and CCL2 are the most extensively
studied chemokines in the context of chronic pain, other
chemokines are now emerging as potential regulators and
thus provide the opportunity for more novel therapies to be
developed.
CCL7/MCP-3
CCL7, otherwise known as MCP-3, has been shown in the
last few years to play a role in the development of chronic
pain in some pre-clinical models. Following partial sciatic
nerve ligation, the expression of CCL7 is elevated in
astrocytes located in the dorsal horn of the spinal cord up
to 2 weeks following the day of surgery (Imai et al. 2013).
This elevation appears to be dependent on the proinﬂamma-
tory cytokine; IL-6, with IL-6 knock-out mice showing no
changes in CCL7 expression after PSNL. Indeed, intrathecal
delivery of recombinant IL-6 into IL-6 knock-out mice
results in an increase in CCL7 mRNA. Both in vitro and
in vivo CCL7 treatment results in microglial activation, which
is suppressed in vivo by intrathecal administration of a
neutralizing antibody against CCL7. In addition, to the
suppression of microglial activation, pain behaviours are also
reduced (Imai et al. 2013). Because of the expression pattern
of CCL7, it is therefore possible that it mediates an astrocyte-
microglia interaction in the context of chronic pain. Indeed,
this has recently been shown to be the case in a spinal nerve
ligation model of chronic pain (Ke et al. 2016). Following
spinal nerve ligation, CCL7 expression in astrocytes in the
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dorsal horn of the spinal cord increased in correlation with
the development of pain. Silencing CCL7 reduced surgery-
induced pain and in vitro, CCL7 has been shown to be
sufﬁcient for the proliferation of astroglial cells (Ke et al.
2016). CCL7 is therefore suggested to be essential for the
development of chronic pain via the promotion of astrocyte
proliferation.
CCL3 and CCL4/MIP-1b
CCL3 has also been recently suggested to play a role in the
development of chronic pain in both traumatic (surgical) and
non-traumatic (non-surgical) pre-clinical models. In a model
utilizing chronic constriction injury of the sciatic nerve, both
CCL3 and its receptor CCR5 were found to increase
alongside microglial activation and the development of both
thermal and mechanical hypersensitivity (Sun et al. 2016).
Intrathecal delivery of a CCL3-neutralizing antibody sup-
pressed the up-regulation of proinﬂammatory cytokines such
as Tumor necrosis factor alpha (TNFa) and IL-1b as well as
the activation of microglial p38 MAPK, indicating that CCL3
regulates, at least in part, the release of proinﬂammatory
cytokines and microglial activation. Furthermore, in CCR5
knock-out mice, pain behaviour was suppressed (Sun et al.
2016). It is important to keep in mind, however, that CCR5 is
not exclusively activated by CCL3 and the effects of the
CCR5 knockout could be a result of disrupting the signalling
of other chemokines such as CCL4 and CXCL13.
CCL3 has also been implicated in non-surgical models
of chronic pain, for instance, CIPN. Following the
treatment of rats with paclitaxel, and the consequential
development of mechanical allodynia, microglial activation
was reported to increase in the dorsal horn of the spinal
cord along with mRNA for both CCL3 and CCR5 (Fig. 1;
Ochi-ishi et al. 2014). The increase in CCL3 is potentially
a result of paclitaxel-induced increase in P2X7 receptors,
which are suggested to trigger the release of CCL3 from
microglia (Kataoka et al. 2009). Intrathecal administration
of a CCL3-neutralizing antibody not only appeared to
attenuate paclitaxel-induced allodynia, but reverse allody-
nia during the maintenance phase, indicating that CCL3
could play a role in both induction and maintenance of
chronic pain potentially making CCL3 a versatile thera-
peutic target.
CCL4, otherwise known as macrophage inﬂammatory
protein 1b shares the CCR5 receptor with CCL3 and has also
been implicated in the regulation of chronic pain in recent
years. Following the induction of a partial sciatic nerve
ligation, CCL4 mRNA increases in both macrophages and
Schwann cells in the periphery as early as day 1 post-surgery
(Fig. 1; Saika et al. 2012). Following local administration of
a CCL4-neutralizing antibody to the region surrounding the
sciatic nerve, both mechanical and thermal allodynia that
occurred as a result of surgery, were prevented. In addition,
PSNL-induced up-regulation of inﬂammatory chemo/cytoki-
nes was also prevented, suggesting that CCL4 could poten-
tially play a peripheral role in the regulation of chronic pain
via regulation of proinﬂammatory chemo/cytokine release. In
addition, administration of the CCR5 antagonist also pre-
vented allodynia in this model (Saika et al. 2012). As
discussed, however, CCR5 is activated by multiple chemoki-
nes and therefore targeting CCR5 will lack the speciﬁcity that
targeting CCL3 or CCL4, speciﬁcally would have.
CCL21
CCL21, another member of the CC subfamily, is another
chemokine that has been suggested to play a role in the
mechanisms underlying chronic pain. Following peripheral
nerve injury, CCL21 expression is rapidly induced in small-
diameter primary sensory neurons and is transported to
central terminals in the dorsal horn, where it is suggested to
increase the expression of the P2X4 receptor in microglia
(Biber et al. 2011). Intrathecal administration of a CCL21-
blocking antibody reduced injury-induced allodynia sug-
gesting that it, at least in part, mediates nociceptive
signalling in this pre-clinical model. Indeed, CCL21 knock-
out mice do not develop allodynia and in these mice, P2X4
receptor expression in microglia does not signiﬁcantly
increase following injury compared to control mice. Criti-
cally, CCL21 injection into CCL21 knock-out mice, results in
the same development of injury-induced allodynia as that
seen in wild-type controls (Biber et al. 2011). In addition,
CCL21 administration in vivo as well as application to
microglia in vitro, is sufﬁcient to increase microglial P2X4
receptor expression. CCL21 has been found to activate both
the CXCR3 and CCR7 receptors, which are expressed by
microglia constitutively and following microglial activation
respectively (Biber et al. 2001; Rappert et al. 2002; Dijkstra
et al. 2004). While knocking out CXCR3 appears to have
no effect on injury-induced mechanical allodynia, CCR7
knock-outs display a delayed onset of allodynia (Biber et al.
2011), suggesting that pronociceptive actions of CCL21 are
more likely to be elicited via activation of the CCR7
receptor.
CXCL13
The most recent chemokine to receive attention in the context
of chronic pain is CXCL13. In the last year, CXCL13 has been
shown to regulate chronic pain in both partial infraorbital
nerve ligation, resulting in trigeminal neuropathic pain
(Zhang et al. 2016) and spinal nerve ligation (Jiang et al.
2016). In the former, both CXCL13 and its receptor CCR5
were found to increase, with the inhibition of either using a
shRNA lentivirus, attenuating allodynia. In the latter,
CXCL13 expression was found to increase in the spinal
cord, and again, suppression of expression using a shRNA
© 2016 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
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lentivirus reduced the injury-associated allodynia. The
potential regulation of pain by CXCL13 has been tentatively
suggested to occur via the activation of astrocytes in the
dorsal horn, with intrathecal injection of CXCL13 resulting in
the activation of astrocytes in naive mice (Jiang et al. 2016).
Conclusion
Chronic pain is a debilitating condition, which is experienced
even when the painful stimulus has been resolved. At
present, clinically available treatments for chronic pain have
limited efﬁcacy and undesirable side-effects. More effective,
novel therapeutic approaches are therefore needed. Although
the mechanisms underlying chronic pain were initially
thought to be neurocentric, it is now accepted that non-
neuronal cells also play a role in nociceptive signalling and
the communication between neurons and non-neuronal cells
in the context of chronic pain has received more attention in
the last decade. One of the signalling pathways known to
mediate the communication between neurons and neighbour-
ing non-neuronal cells is chemokine signalling. Here, we
considered a selection of chemokines (Fig. 1), which, along
with their receptors, have been reported to increase in a
variety of traumatic and non-traumatic pre-clinical models of
chronic pain. Their therapeutic potential has been realized in
the light of the reversal of pain that accompanies their
inhibition. Each chemokine that has been suggested to play a
role in chronic pain comes with its promises and controver-
sies in terms of the development of therapies. In the case of
CX3CL1, for example, the high ﬁdelity of its signalling and
exclusive expression proﬁle means that drugs that are
targeted to this signalling partnership will have highly
speciﬁc effects. While the debatable and variable expression
proﬁle of CCL2/R2 means that currently, targeted therapies
will be difﬁcult to develop.
At present, although chemokine signalling inhibitors are
in their infancy in the clinic, interest has been rapidly
expanding and chemokines, particularly CX3CL1 are
becoming more recognized as innovative therapeutic
targets for a number of pathological conditions. The
CX3CL1 inhibitor, AZD8797, for example, which was
originally developed for use in a pre-clinical model of
multiple sclerosis (Ridderstad Wollberg et al. 2014), has
shown promise in terms of safety and toxicology in
humans and its use in cancer pain may be being
considered, signifying that a new chapter of drug devel-
opment has already begun, with the CX3CL1/CX3CR1
signalling partnership leading the way.
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